1	Long-Term Opioid Use and Emotional, Cognitive, and Sensorimotor Function
2	in Chronic Back Pain
3	
4	Gaelle Rached MD MSc <sup>1,2</sup> , Andrew D. Vigotsky MS <sup>1,2,3</sup> , Paulo Branco PhD <sup>1,2</sup> , Rami Jabakhanji
5	PhD <sup>1,2</sup> , Thomas J. Schnitzer MD PhD <sup>1,4</sup> , A. Vania Apkarian PhD <sup>1,2,4,5</sup> ,
6	and Marwan N. Baliki PhD <sup>1,4,6</sup>
7	
8	<sup>1</sup> Center for Translational Pain Research, and Center of Excellence for Chronic Pain and Drug
9	Abuse Research, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
10	<sup>2</sup> Department of Neuroscience, Northwestern University Feinberg School of Medicine, Chicago,
11	IL, USA
12	<sup>3</sup> Departments of Biomedical Engineering and Statistics, Northwestern University, Evanston, IL,
13	USA
14	<sup>4</sup> Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School
15	of Medicine, Chicago, IL, USA
16	<sup>5</sup> Department of Anesthesiology, Northwestern University Feinberg School of Medicine,
17	Chicago, IL, USA
18	<sup>6</sup> Shirley Ryan Ability Lab, Chicago, IL, USA
19	Correspondence to: Dr A.V. Apkarian
20	E-mail: <u>a-apkarian@northwestern.edu</u>
21	

# 22 Abstract

23	This study examines cognitive, emotional, sensory, and motor function in patients with
24	chronic back pain (CBP) with and without long-term opioid exposure (CBP+O vs. CBP-O) and
25	the influence of race and sex on these outcomes. We recruited 64 CBP+O (mean 7.4 years of
26	opioid use) and 64 matched CBP-O. We collected pain intensity, pain duration, NIH Toolbox
27	outcomes, and measures of opioid use: dosage, duration, blood levels, and withdrawal
28	symptoms. We compared both groups to a normative sample, examined sex and race influences
29	separately, and related CBP+O's NIH Toolbox outcomes to their opioid use measures.
30	CBP+O reported greater pain interference and poorer emotional function. Sex moderated
31	opioid exposure's effects on cognitive performance and social satisfaction, while race moderated
32	motor dexterity and taste outcomes. In CBP+O, 1) opioid dosage was associated with cognitive
33	speed and sensory performance; 2) blood levels of opioids corresponded with poorer attention,
34	motor endurance, and more severe stress and negative affect; 3) opioid use duration was related
35	to improved working memory; while 4) higher withdrawal symptoms were associated with
36	poorer cognitive performance, worsened negative emotions, and decreased grip strength.
37	The study demonstrates both positive and negative outcomes associated with long-term
38	opioid use in CBP, highlighting the need to consider sex- and race-related factors when assessing
39	function in this population.

# 40 Introduction

41 The opioid epidemic is a major public health crisis affecting the United States, with 42 devastating health, economic, and societal costs<sup>1</sup>. Despite controversial evidence of efficacy, 43 opioids are widely used for treating chronic pain and thus contribute to the ongoing epidemic  $2^{-6}$ . 44 Chronic pain and opioid use have largely been studied independently compared to healthy controls, 45 although they are intertwined. Chronic pain is associated with impairments in memory, attention, processing speed, and executive functioning <sup>7, 8</sup>. Similarly, long-term opioid prescription use is 46 47 associated with declines in global cognitive performance, particularly in memory, language, and 48 attention <sup>9</sup>. In addition, prescription opioid misuse and chronic pain worsen negative affect and 49 psychological well-being <sup>10</sup>.

50 Despite overwhelming evidence that chronic pain and long-term opioid use separately 51 impact multiple psychological domains, insufficient research characterizes both conditions 52 concurrently. Consequently, the characteristics of long-term opioid use in chronic pain patients 53 compared to chronic pain without opioids are poorly understood. Here, we investigated the effect 54 of opioids on patients with chronic back pain (CBP) by comparing CBP on long-term opioids 55 (CBP+O) to matched CBP without opioids (CBP-O) using a standard multidimensional 56 assessment tool, the NIH toolbox, which measures cognitive, emotional, sensory, and motor 57 function <sup>11</sup>, providing a holistic picture of neurological and behavioral health. As the patients 58 studied were 58% female and 30% black, we also interrogated sex and race influences on NIH 59 toolbox outcomes. Finally, we examined how opioid dosage, opioid blood levels, opioid duration, 60 and withdrawal symptoms related to the NIH toolbox scores in CBP+O.

61

#### 62 Methods

## 63 Recruitment

64 We recruited 64 CBP+O patients (pain duration > 6 months, mean = 16.5 years) on opioid therapy 65 for at least three months. We selected 64 CBP–O patients (mean pain duration = 16.7 years) from 66 a previously recruited sample (Figure 1). Patients were matched on age, sex, pain intensity, and pain duration using optimal matching <sup>12</sup> (Table 1). All participants were fluent in English, over 18 67 68 years of age, and could understand instructions and questionnaires. Recruitment was from the 69 Northwestern Medicine (NM) healthcare system and Shirley Ryan Ability Lab. Our exclusion 70 criteria included (1) treatment with a spinal cord stimulator; (2) diagnosis of rheumatoid arthritis, 71 ankylosing spondylitis, acute vertebral fractures, fibromyalgia, low back/spine oncologic history, 72 and other comorbid neurological disorders, including major depression and psychiatric disorder 73 requiring treatment; (3) involvement in litigation regarding their back pain, having a disability 74 claim, or receiving workman's compensation; (4) significant comorbid diseases such as 75 uncontrolled hypertension, unstable diabetes mellitus, renal insufficiency, congestive heart failure, 76 coronary or peripheral vascular disease, chronic obstructive lung disease, or malignancy; (5) 77 pregnancy; (6) Beck Depression Inventory (BDI) > 28. The protocols were approved by 78 Northwestern University IRB (STU00207384, STU00205398).

79

#### 80 Measures

81 We collected demographic information from participants, including age, sex, race, and pain 82 intensity (0–10 numeric rating scale, NRS) and duration. Participants completed the four 83 neuropsychological domains of the NIH toolbox: cognition, emotion, motor, and sensation <sup>11</sup>.

84 Tests requiring personal interaction between the experimenter and participants were skipped
85 during the height of the COVID-19 pandemic.

For the CBP+O group, we collected opioid duration and dosage, which we converted to morphine milligram equivalent (MME) using CDC's conversion factors <sup>13</sup>. We also collected plasma to quantify systemic opioid levels. Plasma opioid concentrations were converted to a relative opiate equivalent (ROE), taking into consideration the affinity of each opioid to the muopioid receptor (MOR) <sup>14</sup> and respective molar weights <sup>15-22</sup>. Withdrawal was assessed by the Subjective Opiate Withdrawal Scale (SOWS), a self-report questionnaire to rate common signs and symptoms of opiate withdrawal <sup>23</sup>.

93

## 94 Blood sample collection, analysis, and ROE calculations

95 We also collected blood samples from participants to quantify systemic levels of opioids. The 96 concentrations of eight analytes (oxymorphone, hydromorphone, oxycodone, hydrocodone, 97 fentanyl, buprenorphine, methadone and tramadol) and the presence of three others (morphine, 98 codeine, and heroin) in plasma were determined by liquid chromatography-tandem mass 99 spectrometry after sample preparation by solid-phase extraction, using deuterated analogs 100 (oxymorphone-D3, hydromorphone-D6, oxycodone-D6, hydrocodone-D6, buprenorphine-D4, 101 methadone-D3, and tramadol-C13D3) as internal standards, based on the method reported by 102 Langman et al <sup>24</sup>. One hundred microliters of the plasma sample were diluted with 300 uL of 1% 103 acetic acid, vortexed and loaded onto a Phenomenex Strata-X-Drug B 96-well plate. After washing 104 with 100 mM sodium acetate buffer and methanol, the analytes were eluted with an ethyl 105 acetate/isopropanol/ammonium hydroxide (7:2:1 v/v/v) mixture and evaporated to dryness under 106 a stream of nitrogen. The samples were reconstituted in 15% methanol in water and analyzed by a

107 Sciex 6500+ Qtrap LC-MS/MS system equipped with a Shimadzu Nexera2 UPLC system. 108 Samples were eluted from a Phenomenex Kinetex 2.6 µm Biphenyl (50 x 2.1 mm) column with a 109 mobile phase consisting of A: water with 0.1 % formic acid and B: methanol with 0.1 % formic 110 acid at a flow rate of 0.6 mL/min with a gradient from 10% B to 85% B in 4.5 min. 111 Samples were run in duplicate, and the average opioid concentration was used. The opioid 112 concentrations were then converted to a relative opiate equivalent (ROE), taking into consideration 113 the affinity of each opioid to the mu-opioid receptor (MOR)<sup>14</sup>, and the respective molar weights 114 <sup>15-22</sup>. We realize that limiting tramadol to its MOR affinity excludes other aspects of the tramadol 115 effect; however, we are specifically interested in the opiate activity on MOR. Samples with peak

116 presence of opioids below the lower limit of quantitation were imputed as the halfway point from 117 zero to the measurable lower quantifiable threshold.

118

## 119 Statistical Analysis

120 NIH toolbox differences between CBP+O and CBP-O were analyzed using multiple 121 regression with age, gender, pain intensity, and pain duration included as covariates—the same 122 covariates on which the participants were matched. Because we used one-to-one matching, we 123 calculated cluster-robust variances. For each outcome, each group's score was also compared to 124 normative data using a one-sample *t*-test, with a mean T-score of 50 and a standard deviation of 125 10 in the normative sample. To investigate the effects of sex and race, we performed separate 126 multiple regressions: one with a sex-by-group interaction and another with a race-by-group 127 interaction.

128 To map NIH toolbox scores onto CBP–O's opioid parameters, we calculated rank-based 129 partial correlations (95% CI) between the NIH toolbox outcomes and measures of opioid use,

adjusted for age, sex, pain intensity, and pain duration. To do so, (1) all the measures were
converted to ranks, (2) opioid use metrics and NIH toolbox metrics were residualized with respect
to the covariates, and (3) we calculated Pearson correlation coefficients using the residuals.
Measures of opioid use were quantified in terms of opioid dosage (MME), opioid blood level
(ROE), opioid duration (years), and opioid withdrawal (SOWS). MME and ROE were logtransformed due to the skewed distributions.

136

# 137 **Results**

138 We independently evaluated the groups' NIH toolbox outcomes and contrasted the groups 139 with and without sex and race interactions (figure 2). In the cognition domain, Flanker's attentional 140 inhibitory control test was most perturbed in both groups compared to normative values, while 141 picture vocabulary was worse in CBP+O. In the emotion domain, CBP+O was worse than CBP-O 142 on all five tests, especially regarding social satisfaction. All six motor tests were abnormal but with 143 divergent differences: balance and walking endurance were similarly diminished in both groups; 144 grip strength was worse in CBP-O; and dexterity was worse in CBP+O. In the sensation domain, 145 taste was similarly worse than normative values across both groups and pain interference was 146 worse in both groups, but more so in CBP+O.

Sex moderated the effects of opioid exposure on social satisfaction, grip strength, and
walking endurance. Race moderated the group effect on grip strength, dexterity, stress, working
memory, and flanker inhibitory control.

Adjusted partial correlations within the CBP+O group examined the influence of opioid use measures on NIH toolbox outcomes (Figure 3): 1) Higher opioid use dosages were related to better processing speed, salt and odor identification, and worse dexterity. 2) Greater opioid blood

153 levels were related to higher stress, decreased well-being, increased negative affect, and 154 diminished walking ability. 3) Longer durations of opioid use were related to better memory 155 performance. 4) More severe opioid withdrawal signs (SOWS) were related to worse vocabulary 156 and memory, worse outcomes for all five emotion measures, lower grip strength and quinine taste, 157 and increased pain interference.

158

# 159 **Discussion**

160 Our study examined the association of chronic pain and long-term opioid use on cognitive, 161 sensory, emotional, and motor functioning. Both CBP+O and CBP-O experienced more pain interference than the normative sample. Although our study groups were matched on back pain 162 163 intensity and duration, CBP+O exhibited more pain interference, which we surmise may be related 164 to opioid-induced hyperalgesia <sup>25, 26</sup>; these effects were not moderated by race and sex. Within 165 CBP+O, pain interference was most strongly related to withdrawal signs, weakly related to opioid dosage (consistent with earlier data <sup>27</sup>) and opioid blood levels, and appeared to be unrelated to the 166 duration of opioid use (contrary to an earlier report  $^{28}$ ). 167

168 The emotional domain of the NIH toolbox was the dimension most perturbed by opioid 169 exposure. All five emotion-related tests exhibited poorer outcomes in CBP+O, especially 170 regarding social satisfaction, which was moderated by sex. Like pain interference, all five 171 measures were associated with withdrawal and less consistently with blood levels of opioids. 172 Given that this is a cross-sectional observational study, causal relationships remain unclear. 173 However, given that pain interference and emotion domain were all related to state measures 174 (blood opioids, withdrawal), it is suggested that the worsening of these outcomes is a consequence 175 of opioid exposure.

176 In the motor domain, some measures were improved, and others were exacerbated in 177 CBP+O. Moreover, these outcomes were differentially moderated by race. In the sensory taste 178 outcomes, both CBP-O and CBP+O showed similar abnormalities moderated by race. In the 179 cognitive domain, CBP+O and CBP-O performed poorly on attentional tasks, consistent with previous studies demonstrating that chronic pain is associated with impaired general cognitive 180 181 functions <sup>8, 29, 30</sup>. These results have broad implications for the daily functioning and rehabilitation 182 of individuals with chronic pain. Previous results regarding long-term opioid use and cognition remain contradictory and inconclusive <sup>31-36</sup>. 183

Disparities in cognitive performance among individuals with chronic pain relative to race highlight the need for further investigation and consideration of race-related factors when assessing and treating cognitive impairments in this population. Interestingly, sex effects were less prominent than race and included specific outcomes in cognition, emotion, and motor domains. Both factors remain to be studied more thoroughly in the future.

This study has three noteworthy limitations. First, our cross-sectional design makes the causality unclear. However, this is partially overcome by our matching and relating outcomes to opioid measures. Second, we excluded patients who have a clinical diagnosis of depression and have a BDI > 28, decreasing the generalizability of our results while allowing us to characterize behavior and functioning in patients with minimal psychiatric confounds. Third, our matched sample comes from a previously recruited sample. Since the data were collected by different people at different time points, potentially affecting our measured values.

196

197

# 199 Conclusion

200 Our study provides important insights into the impact of chronic pain and long-term opioid 201 use on various domains of functioning. Chronic pain was associated with cognitive, sensory, 202 emotional, and motor impairments, with attention deficits being a prominent feature. Our results 203 suggest that long-term opioid use may not significantly contribute to cognitive impairments 204 beyond chronic pain itself. However, long-term opioid use is associated with worse emotional 205 functioning. Additionally, our study highlights potential race and sex disparities in cognitive 206 performance and social satisfaction, respectively, among individuals with chronic pain. Overall, 207 our study furthers our understanding of the complex interactions between chronic pain and long-208 term opioid use in different aspects of patients' lives, which can inform more effective treatment 209 strategies for this patient population.

210

## Table 1: Demographic characteristics of patients with chronic back pain not

#### 212 consuming opioids (CBP – O) and on long-term opioids (CBP + O)

	CBP - O (N=64)	CBP + O (N=64)	P-value <sup>®</sup>
Age (years)			
Mean (SD)	59.3 (12.6)	59.6 (11.2)	0.90
Sex			
Male	28 (43.8%)	24 (37.5%)	0.59
Female	36 (56.3%)	40 (62.5%)	
Race			0.01
Black/African American	20 (31.3%)	20 (31.3%)	
White	33 (51.6%)	43 (67.2%)	
Other	10 (15.6%)	1 (1.6%)	
Missing	1 (1.6%)	0 (0%)	
Pain Intensity (0-10)			
Mean (SD)	5.22 (2.20)	5.33 (1.98)	0.77

	CBP - O (N=64)	CBP + O (N=64)	P-value
Pain Duration (years)			
Mean (SD)	16.5 (19.3)	16.7 (12.2)	0.94
Opioid Dosage (MME)			
Mean (SD)	NA	66.5 (196)	NA
Median [Min, Max] ª	NA	20.0 [5.00, 1440]	
Missing	NA	5 (7.8%)	
Opioid Blood Level (ROE)			
Mean (SD)	NA	0.0146 (0.0736)	NA
Median [Min, Max] ª	NA	0.000400 [0, 0.552]	
Missing	NA	7 (10.9%)	
Opioid Withdrawal (SOWS)			
Mean (SD)	NA	8.69 (8.42)	NA
Opioid Use Duration (years)			
Mean (SD)	NA	7.36 (6.14)	NA
Opioid Type (N)⁵			
Buprenorphine	0	1	NA
Codeine	0	2	NA
Fentanyl Patch	0	3	NA
Hydrocodone	0	25	NA
Hydromorphone	0	1	NA
Methadone	0	2	NA
Morphine	0	3	NA
Oxycodone	0	11	NA
Oxymorphone	0	1	NA
Tapentadol	0	1	NA
Tramadol	0	25	NA

<sup>a</sup> MME and ROE were log-transformed due to their respective skewed distribution; thus, median, and interquartile range (IQR) is also

215 reported.

216 <sup>b</sup> Eleven patients were taking two types of opioids thus the total is higher than 100%.

217 ° P values were calculated using a *t*-test for continuous variables and chi-square test for categorical variables. NA = not available.

# 219 Figures & Legends



223 Figure 1: Recruitment flowchart of patients with chronic back pain not consuming

```
224 opioids (CBP – O) and on long-term opioids (CBP + O).
```

.





Figure 2: The Emotional, Cognitive, and Sensorimotor Scores in Patients with Chronic Back Pain with (CBP+O) or without Long-Term Opioid Use (CBP-O) and Their Relationships with Sex and Race.

(A) Estimated marginal means (95% CI) of the NIH toolbox components for patients with
chronic back pain with (green, *n*=64) and without (pink, *n*=64) long-term opioids. Point
estimates and their CIs were obtained using a linear regression adjusted for age, sex,
pain intensity, and pain duration with cluster-robust variances. The grey line indicates the

241 mean in a normative sample (normative T-score =  $50 \pm 10$ , n =1000). Each group can 242 thus be directly compared to the normative sample using their estimate and 95% CI. The 243 number of participants per group per measure is shown. The second column shows group 244 differences (CBP+O minus CBP-O, 95% CI) for each subscale. Data points with CIs not crossing the line on 0 indicate P < 0.05. The third column shows opioid group by sex 245 246 interactions (95% CI). Positive values indicate that the CBP+O minus CBP-O is greater 247 in females, and negative values indicate the opposite (CBP+O minus CBP-O is greater 248 in males). The fourth column shows the opioid group by race interaction (95% CI); positive 249 values indicate that CBP+O minus CBP-O is greater in blacks, and negative values 250 indicate the opposite (CBP+O minus CBP-O is greater in whites). We did not include the 251 "Other" category for race in the analysis. (B) Group differences in Grip-Strength 252 Dominant, Social Satisfaction, 2min Walk Endurance stratified by sex. (C) Group 253 differences in Grip-Strength Dominant, Social Satisfaction, 2min Walk Endurance 254 stratified by race. Box plots show the upper and lower quartiles and medians, and point 255 estimates show the mean.

256

257



259

Figure 3: The Relationship between Emotional, Cognitive, and Sensorimotor Scores and Opioid Dosage, Opioid Blood Level, Opioid Use Duration, and Withdrawal Signs in Patients with Chronic Back Pain with Long-Term Opioid Use (CBP+O).

(A) Partial rank correlations (95% CI) between the NIH Toolbox items and measures of opioid use adjusted for age, sex, pain intensity, and pain duration. Measures of opioid use are quantified in terms of opioid dosage (log(MME)), opioid blood level (log(ROE)), opioid duration (years) and opioid withdrawal (SOWS). The numbers of participants per NIH Toolbox test and per opioid use measure are represented on the plot. (B) Scatter plots showing the partial rank correlations between some NIH Toolbox items and measures of opioid use. Nine-Hole Pegboard Dexterity-Dominant was correlated with

271	opioid dosage (log(MME)), 2-Minute Walk Endurance with opioid blood level (log(ROE)),
272	List Sorting Working Memory with opioid duration, and Negative Affect and Picture
273	Vocabulary with Withdrawal Severity (SOWS). Solid lines in the scatter plots show fitted
274	lines and shaded areas are 95% confidence intervals. Since we used partial rank
275	correlations, the axes in (B) are based on residualized ranks rather than original units.
276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300	
301 302	

# 303 Acknowledgments:

- 304 This work made use of the Mary Beth Donnelley Clinical Pharmacology Core at Northwestern
- 305 University, which has received support from the NIH (1S10OD012016-01 / 1S10RR019071-
- 306 01A1), Soft and Hybrid Nanotechnology Experimental (SHyNE) Resource (NSF ECCS-
- 307 1542205), the State of Illinois, and the International Institute for Nanotechnology (IIN).
- 308 Meghan Ford, data collection
- 309 Elizabeth Yan, data collection
- 310 Maryam Abdallah, data collection
- 311 Byron K Yip, data collection
- 312 Santiago Espinosa, data collection
- 313 Rahia Parveen Shuaib, data collection

# 314 **References**

315 1. Volkow ND, Blanco C. The changing opioid crisis: development, challenges and

316 opportunities. Mol Psychiatry. 2021;26(1):218-33. Epub 20200204. doi: 10.1038/s41380-020-

317 0661-4. PubMed PMID: 32020048; PMCID: PMC7398847.

318 2. Nury E, Schmucker C, Nagavci B, Motschall E, Nitschke K, Schulte E, Wegwarth O,

319 Meerpohl JJ. Efficacy and safety of strong opioids for chronic noncancer pain and chronic low

- back pain: a systematic review and meta-analyses. Pain. 2022;163(4):610-36. Epub 2021/07/31.
- doi: 10.1097/j.pain.00000000002423. PubMed PMID: 34326292.

322 3. Volkow ND, McLellan AT. Opioid Abuse in Chronic Pain — Misconceptions and
 323 Mitigation Strategies. New England Journal of Medicine. 2016;374(13):1253-63. doi:
 324 10.1056/NEJMra1507771. PubMed PMID: 27028915.

325 4. Nagpal AS, Eckmann M, Weinstein SM. Maintaining Opioid Prescription for Chronic
326 Back Pain: Pro Versus Con. PM R. 2018;10(1):83-9. doi: 10.1016/j.pmrj.2017.12.002. PubMed
327 PMID: 29413121.

328 5. Voon P, Karamouzian M, Kerr T. Chronic pain and opioid misuse: a review of reviews.

329 Subst Abuse Treat Prev Policy. 2017;12(1):36. Epub 20170815. doi: 10.1186/s13011-017-0120-

330 7. PubMed PMID: 28810899; PMCID: PMC5558770.

331 6. Dahlhamer JM, Connor EM, Bose J, Lucas JL, Zelaya CE. Prescription Opioid Use Among

Adults With Chronic Pain: United States, 2019. Natl Health Stat Report. 2021(162):1-9. Epub

333 2021/09/16. PubMed PMID: 34524076.

Higgins DM, Martin AM, Baker DG, Vasterling JJ, Risbrough V. The Relationship
Between Chronic Pain and Neurocognitive Function: A Systematic Review. Clin J Pain.
2018;34(3):262-75. doi: 10.1097/ajp.0000000000000536. PubMed PMID: 28719507; PMCID:
PMC5771985.

Moriarty O, McGuire BE, Finn DP. The effect of pain on cognitive function: A review of
 clinical and preclinical research. Progress in Neurobiology. 2011;93(3):385-404. doi:
 https://doi.org/10.1016/j.pneurobio.2011.01.002.

Warner NS, Hanson AC, Schulte PJ, Habermann EB, Warner DO, Mielke MM.
Prescription opioids and longitudinal changes in cognitive function in older adults: A populationbased observational study. Journal of the American Geriatrics Society. 2022;70(12):3526-37. doi:
<a href="https://doi.org/10.1111/jgs.18030">https://doi.org/10.1111/jgs.18030</a>.

Martel MO, Dolman AJ, Edwards RR, Jamison RN, Wasan AD. The Association Between
Negative Affect and Prescription Opioid Misuse in Patients With Chronic Pain: The Mediating

- 347 Role of Opioid Craving. The Journal of Pain. 2014;15(1):90-100. doi:
  348 https://doi.org/10.1016/j.jpain.2013.09.014.
- 349 11. NIH. NIH Toolbox® Scoring and Interpretation Guide for the iPad: National Institutes of
- 350 Health and Northwestern University
- 351 ; 2021 [updated 5/25/2021; cited 2022 9/8/2022].
- 12. Ho D, Imai K, King G, Stuart EA. MatchIt: Nonparametric Preprocessing for Parametric
- 353 Causal Inference. Journal of Statistical Software. 2011;42(8):1 28. doi: 10.18637/jss.v042.i08.
- 354 13. Prevention CfDCa. Analyzing prescription data and morphine milligram equivalents355 (MME)2021.
- 356 14. Volpe DA, Tobin GAM, Mellon RD, Katki AG, Parker RJ, Colatsky T, Kropp TJ, Verbois
- 357 SL. Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid
- drugs. Regulatory Toxicology and Pharmacology. 2011;59(3):385-90. doi:
  https://doi.org/10.1016/j.yrtph.2010.12.007.
- 360 15. Information NCfB. PubChem Compound Summary for CID 5284604, Oxymorphone.361 2022.
- 16. Information NCfB. PubChem Compound Summary for CID 5284603, Oxycodone2022.
- 17. Information NCfB. PubChem Compound Summary for CID 3345, Fentanyl2022.
- 364 18. Information NCfB. PubChem Compound Summary for CID 5284570,
  365 Hydromorphone2022.
- 366 19. Information NCfB. PubChem Compound Summary for CID 5284569, Hydrocodone2022.
- 367 20. Information NCfB. PubChem Compound Summary for CID 5284371, Codeine2022.
- 368 21. Information NCfB. PubChem Compound Summary for CID 33741, Tramadol2022.
- 369 22. Information NCfB. PubChem Compound Summary for CID 4095, Methadone2022.

370 23. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new
371 rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293-308. doi:
372 10.3109/00952998709001515. PubMed PMID: 3687892.

Langman LJ, Korman E, Stauble ME, Boswell MV, Baumgartner RN, Jortani SA.
Therapeutic monitoring of opioids: a sensitive LC-MS/MS method for quantitation of several
opioids including hydrocodone and its metabolites. Ther Drug Monit. 2013;35(3):352-9. doi:
10.1097/FTD.0b013e318283e29a. PubMed PMID: 23666565.

25. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of
opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145-61. PubMed PMID: 21412369.

Wilson SH, Hellman KM, James D, Adler AC, Chandrakantan A. Mechanisms, diagnosis,
prevention and management of perioperative opioid-induced hyperalgesia. Pain Manag.
2021;11(4):405-17. Epub 20210329. doi: 10.2217/pmt-2020-0105. PubMed PMID: 33779215;
PMCID: PMC8023328.

27. Denawa Y, Kurtz W, Conermann T. The Social and Functional Implications of HighVersus Low-Dose Opioids on Chronic Non-Cancer Pain. Pain Physician. 2019;22(4):401-11.
PubMed PMID: 31337176.

386 28. Morasco BJ, Yarborough BJ, Smith NX, Dobscha SK, Deyo RA, Perrin NA, Green CA. Higher Prescription Opioid Dose is Associated With Worse Patient-Reported Pain Outcomes and 387 388 More Health Care Utilization. The Journal of Pain. 2017;18(4):437-45. doi: 389 https://doi.org/10.1016/j.jpain.2016.12.004.

29. Prefontaine K, Rochette A. A Literature Review on Chronic Pain: The Daily Overcoming
of a Complex Problem. British Journal of Occupational Therapy. 2013;76(6):280-6. doi:
10.4276/030802213x13706169932905.

393 30. Sjøgren P, Christrup LL, Petersen MA, Højsted J. Neuropsychological assessment of 394 chronic non-malignant pain patients treated in a multidisciplinary pain centre. Eur J Pain. 395 2005;9(4):453-62. Epub 20041105. doi: 10.1016/j.ejpain.2004.10.005. PubMed PMID: 15979026. 396 31. Kendall SE, Sjøgren P, Pimenta CAM, Højsted J, Kurita GP. The cognitive effects of 397 opioids in chronic non-cancer pain. Pain. 2010;150(2):225-30. doi: 10.1016/j.pain.2010.05.012. 398 PubMed PMID: 20554115. 399 32. Jamison RN, Schein JR, Vallow S, Ascher S, Vorsanger GJ, Katz NP. Neuropsychological

400 effects of long-term opioid use in chronic pain patients. J Pain Symptom Manage. 2003;26(4):913-

401 21. doi: 10.1016/s0885-3924(03)00310-5. PubMed PMID: 14527760.

33. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy
for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348(13):1223-32. doi:
10.1056/NEJMoa021420. PubMed PMID: 12660386.

405 34. Tassain V, Attal N, Fletcher D, Brasseur L, Dégieux P, Chauvin M, Bouhassira D. Long
406 term effects of oral sustained release morphine on neuropsychological performance in patients
407 with chronic non-cancer pain. Pain. 2003;104(1-2):389-400. doi: 10.1016/s0304-3959(03)00047408 2. PubMed PMID: 12855350.

35. Schiltenwolf M, Akbar M, Hug A, Pfuller U, Gantz S, Neubauer E, Flor H, Wang H.
Evidence of Specific Cognitive Deficits in Patients with Chronic Low Back Pain under Long-Term
Substitution Treatment of Opioids. Pain physician. 2014;17:9-20. doi: 10.36076/ppj.2014/17/9.

412 36. Lee DM, Pendleton N, Tajar A, O'Neill TW, O'Connor DB, Bartfai G, Boonen S,

413 Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean MEJ,

414 Punab M, Silman AJ, Vanderschueren D, Moseley CM, Wu FCW, McBeth J. Chronic widespread

415 pain is associated with slower cognitive processing speed in middle-aged and older European men.

# 416 Pain. 2010;151(1):30-6. Epub 20100619. doi: 10.1016/j.pain.2010.04.024. PubMed PMID:

- 417 20646831.
- 418